NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request HearingAccesswire • 04/19/24
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist PlatformAccesswire • 03/20/24
NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.Accesswire • 12/01/23
NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic HypersomniaAccesswire • 11/27/23
NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge LoanAccesswire • 11/16/23
NLS Pharmaceutics shares rise as narcolepsy treatment moves to phase 3 studiesMarket Watch • 07/03/23
NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study ProtocolAccesswire • 07/03/23
CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-VestAccesswire • 06/19/23
NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-VestAccesswire • 06/15/23
NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of MazindolAccesswire • 06/14/23